Pharmamar pays dearly for the puncture of its star drug in the results

Pharmamar pays dearly for the puncture of its star drug in the results

Pharmamar shares plummeted 11 percent, the biggest drop since January, after trading quarterly results that dismantled even what this Wednesday was the best value of the IBEX 35. The figures were in line with the analysts’ projections, but the drop in Zepzelca’s turnover and the higher spending on R&D uncovered the thunder box. The company …

Pharmamar pays dearly for the puncture of its star drug in the results Read More »